(CRMZ)
Preview

This is a Preview, click here for the full commercial credit report.
Thallion Pharmaceuticals Inc.
7150 Alexander-Fleming
Phone: (514) 940-3600Montreal, QC  H4S 2C8  CanadaTicker: TLN

Business Summary
Thallion Pharmaceuticals Inc. is a biotechnology company focused on developing new pharmaceutical treatments for oncology and infectious diseases. The Company’s product candidates include Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections, and TLN-4601, a small molecule with potential efficacy in multiple oncology indications. The Company’s Shigamabs product consists of two monoclonal antibodies designed to bind specifically and exclusively to Shigatoxin 1 (Stx1) and Shigatoxin 2 (Stx2) secreted by Shigatoxin-producing E. coli (STEC). The Company has completed four Phase I clinical trials evaluating the safety of Shigamabs, which have demonstrated that the antibodies are safe and well tolerated when administered both individually and in combination at various dose levels. Derived from the Company’s DECIPHER technology, TLN-4601 is a natural product candidate derived from a nonpathogenic microorganism.
(Source: ARS)
 
Financial Information
Financial Ratings:Z'' Score  FRISK Score
Latest Financial Statements
and Analyses:
5/31/2010    Annual Financials    Quarterly Financials    
Current Fiscal Period:2Q 2010
Fiscal Year End:December
Last Audit:11/30/2009
Auditors:KPMG LLP
Audit Opinion:Unqualified
 
Industries
Type
Code
Description
SectorHEALTHHealthcare
IndustryBIOTRXBiotechnology & Drugs
SIC2835In Vitro And In Vivo Diagnostic Substances
8731Commercial Physical And Biological Research
NAICS325412Pharmaceutical Preparation Manufacturing
54171Research and Development in the Physical, Engineering, and Life Sciences
 
Management

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the BoardLloyd M. Segal461/11/20103/14/2007
Chief Executive Officer, DirectorAllan Mandelzys 2/23/20104/24/2007
Chief Financial Officer, Corporate SecretaryMichael Singer 3/14/20073/14/2007
5 additional Management records available in full report.
 
Business Names
Business Name
Ecopia BioSciences Inc.
Thallion Pharmaceuticals Inc.
 
General Information
Number of Employees:18 (As of 11/30/2009)
Outstanding Shares:32,194,566 (As of 7/12/2010)
Shareholders:114 
Stock Exchange:TSE
Fax Number:(514) 228-3622
 

Home | Directory | About Us | Products | Service Options | Pricing | Register | Contact Us | Testimonials | Hours of Availability | Careers | Events | Resources | Investors | Sign In
 
Copyright © by CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.
By using this website, you accept the Terms of Use Agreement.
Contact Us: 845.230.3000